{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T23:30:06Z","timestamp":1791847806329,"version":"4.3.4"},"reference-count":93,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2019,6,4]],"date-time":"2019-06-04T00:00:00Z","timestamp":1559606400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"DOI":"10.3389\/fimmu.2019.01238","type":"journal-article","created":{"date-parts":[[2019,6,4]],"date-time":"2019-06-04T04:45:04Z","timestamp":1559623504000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":121,"title":["Dipeptidyl Peptidase-4 Inhibitor-Associated Bullous Pemphigoid"],"prefix":"10.3389","volume":"10","author":[{"given":"Kaisa","family":"Tasanen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Outi","family":"Varpuluoma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wataru","family":"Nishie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2019,6,4]]},"reference":[{"key":"B1","first-page":"14","article-title":"New diagnostic tool for bullous pemphigoid: full-length BP180 ELISA","volume":"39","author":"Nishie","year":"2017","journal-title":"Pract Dermatol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1111\/j.1365-2133.2012.11108.x","article-title":"Clinical presentation and diagnostic delay in bullous pemphigoid: a prospective nationwide cohort","volume":"167","author":"Della Torre","year":"2012","journal-title":"Br J Dermatol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1016\/j.jaad.2017.10.035","article-title":"Nonbullous cutaneous pemphigoid: a systematic review","volume":"78","author":"Lamberts","year":"2018","journal-title":"J Am Acad Dermatol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/j.jdermsci.2013.12.001","article-title":"Update on the pathogenesis of bullous pemphigoid: an autoantibody-mediated blistering disease targeting collagen XVII","volume":"73","author":"Nishie","year":"2014","journal-title":"J Dermatol Sci."},{"key":"B5","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1016\/S0140-6736(12)61140-4","article-title":"Pemphigoid diseases","volume":"381","author":"Schmidt","year":"2013","journal-title":"Lancet."},{"key":"B6","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1016\/j.jaut.2008.08.009","article-title":"Subepidermal blistering induced by human autoantibodies to BP180 requires innate immune players in a humanized bullous pemphigoid mouse model","volume":"31","author":"Liu","year":"2008","journal-title":"J Autoimmunity."},{"key":"B7","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1038\/nm1496","article-title":"Humanization of autoantigen","volume":"13","author":"Nishie","year":"2007","journal-title":"Nat Med."},{"key":"B8","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1016\/j.jdermsci.2015.03.002","article-title":"IgE autoantibodies in bullous pemphigoid: supporting role, or leading player?","volume":"78","author":"Ujiie","year":"2015","journal-title":"J Dermatol Sci."},{"key":"B9","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1111\/j.1365-4632.2009.04345","article-title":"Pemphigus vulgaris is the most common autoimmune bullous disease in northwestern Romania","volume":"49","author":"Baican","year":"2010","journal-title":"Int J Dermatol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"1998","DOI":"10.1038\/jid.2012.35","article-title":"Incidence and mortality of bullous pemphigoid in France","volume":"132","author":"Joly","year":"2012","journal-title":"J Invest Dermatol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"220","DOI":"10.3389\/fmed.2018.00220","article-title":"The growing incidence of bullous pemphigoid: overview and potential explanations","volume":"5","author":"Kridin","year":"2018","journal-title":"Front Med."},{"key":"B12","doi-asserted-by":"publisher","first-page":"1223","DOI":"10.1111\/bjd.13189","article-title":"Increasing incidence of bullous pemphigoid in northern Finland: a retrospective database study in Oulu university hospital","volume":"171","author":"F\u00f6rsti","year":"2014","journal-title":"Br J Dermatol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1111\/j.1365-2133.2005.06662.x","article-title":"Annual incidence and mortality of bullous pemphigoid in the Grampian region of north-east Scotland","volume":"153","author":"Gudi","year":"2005","journal-title":"Br J Dermatol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"a180","DOI":"10.1136\/bmj.a180","article-title":"Bullous pemphigoid and pemphigus vulgaris\u2013incidence and mortality in the UK: population based cohort study","volume":"337","author":"Langan","year":"2008","journal-title":"BMJ."},{"key":"B15","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.jaad.2014.02.030","article-title":"Incidence of bullous pemphigoid and mortality of patients with bullous pemphigoid in Olmsted county, Minnesota, 1960 through 2009","volume":"71","author":"Brick","year":"2014","journal-title":"J Am Acad Dermatol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1111\/bjd.12806","article-title":"Mortality of bullous pemphigoid in Singapore: risk factors and causes of death in 359 patients seen at the national skin centre","volume":"170","author":"Cai","year":"2014","journal-title":"Br J Dermatol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"758","DOI":"10.2340\/00015555-2347","article-title":"Risk of death in bullous pemphigoid: a retrospective database study in Finland","volume":"96","author":"F\u00f6rsti","year":"2016","journal-title":"Acta Dermato-Venereol."},{"key":"B18","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1111\/jdv.12065","article-title":"Mortality of bullous pemphigoid in the first year after diagnosis: a retrospective study in a Spanish medical centre","volume":"28","author":"Gual","year":"2014","journal-title":"J Eur Acad Dermatol Venereol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1016\/j.jaad.2014.05.006","article-title":"Mortality of patients with bullous pemphigoid in Korea","volume":"71","author":"Lee","year":"2014","journal-title":"J Am Acad Dermatol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1111\/j.1365-2133.2009.09300.x","article-title":"Incidence of bullous pemphigoid and pemphigus in Switzerland: a 2-year prospective study","volume":"161","author":"Marazza","year":"2009","journal-title":"Br J Dermatol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"238","DOI":"10.3389\/fmed.2018.00238","article-title":"Comorbidities and treatment strategies in bullous pemphigoid: an appraisal of the existing litterature","volume":"5","author":"Bech","year":"2018","journal-title":"Front Med."},{"key":"B22","doi-asserted-by":"publisher","first-page":"1709","DOI":"10.1111\/jdv.14312","article-title":"Multimorbidity in bullous pemphigoid: a case-control analysis of bullous pemphigoid patients with age- and gender-matched controls","volume":"10","author":"Sim","year":"2017","journal-title":"J Eur Acad Dermatol Venereol."},{"key":"B23","doi-asserted-by":"publisher","first-page":"13","DOI":"10.5021\/ad.2018.30.1.13","article-title":"Mortality and comorbidity profiles of patients with bullous pemphigoid in Korea","volume":"30","author":"Jeon","year":"2018","journal-title":"Ann Dermatol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"1486","DOI":"10.1111\/bjd.15405","article-title":"Increased frequency of multiple sclerosis among patients with bullous pemphigoid: a population-based cohort study on comorbidities anchored around the diagnosis of bullous pemphigoid","volume":"176","author":"Kibsgaard","year":"2017","journal-title":"Br J Dermatol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1111\/ajd.12899","article-title":"Association between bullous pemphigoid and psoriasis: systematic review and meta-analysis of case-control studies","volume":"60","author":"Phan","year":"2019","journal-title":"Aust J Dermatol."},{"key":"B26","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1016\/j.jaad.2017.05.006","article-title":"Association of bullous pemphigoid with malignancy: a systematic review and meta-analysis","volume":"77","author":"Atzmony","year":"2017","journal-title":"J Am Acad Dermatol."},{"key":"B27","doi-asserted-by":"publisher","first-page":"72","DOI":"10.2340\/00015555-2930","article-title":"Mortality in patients with bullous pemphigoid: a retrospective cohort study, systematic review and meta-analysis","volume":"99","author":"Kridin","year":"2019","journal-title":"Acta Dermato-Venereol."},{"key":"B28","doi-asserted-by":"publisher","first-page":"1228","DOI":"10.1111\/exd.13401","article-title":"Neurological and psychiatric associations in bullous pemphigoid\u2013more than skin deep?","volume":"26","author":"F\u00f6rsti","year":"2017","journal-title":"Exp Dermatol."},{"key":"B29","doi-asserted-by":"publisher","first-page":"2007","DOI":"10.1111\/jdv.13660","article-title":"Bullous pemphigoid and its association with neurological diseases: a systematic review and meta-analysis","volume":"30","author":"Lai","year":"2016","journal-title":"J Eur Acad Dermatol Venereol."},{"key":"B30","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1038\/jid.2010.357","article-title":"The relationship between neurological disease and bullous pemphigoid: a population-based case\u2013control study","volume":"131","author":"Langan","year":"2011","journal-title":"J Invest Dermatol."},{"key":"B31","doi-asserted-by":"publisher","first-page":"240570","DOI":"10.1155\/2013\/240570","article-title":"Collagen XVII: a shared antigen in neurodermatological interactions?","volume":"2013","author":"Sepp\u00e4nen","year":"2013","journal-title":"Clin Dev Immunol."},{"key":"B32","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.jid.2016.09.010","article-title":"Increased levels of the bullous pemphigoid BP180 autoantibody are associated with more severe dementia in Alzheimer's disease","volume":"137","author":"Kokkonen","year":"2017","journal-title":"J Invest Dermatol."},{"key":"B33","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1016\/j.jid.2015.12.005","article-title":"Autoantibodies to collagen XVII are present in parkinson's disease and localize to tyrosine-hydroxylase positive neurons","volume":"136","author":"Messingham","year":"2016","journal-title":"J Invest Dermatol."},{"key":"B34","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1016\/j.jid.2018.09.010","article-title":"BP180 autoantibodies target different epitopes in multiple sclerosis or alzheimer's disease than in bullous pemphigoid","volume":"139","author":"Tuusa","year":"2019","journal-title":"J Invest Dermatol."},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2019.02.017","article-title":"Drugs used for neurological and psychiatric conditions increase the risk of bullous pemphigoid: a case-control study","author":"Varpuluoma","year":"2019","journal-title":"J Am Acad Dermatol."},{"key":"B36","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1111\/jdv.12366","article-title":"Drug-induced pemphigoid: a review of the literature","volume":"28","author":"Stavropoulos","year":"2014","journal-title":"J Eur Acad Dermatol Venereol."},{"key":"B37","doi-asserted-by":"publisher","first-page":"e133","DOI":"10.2337\/dc11-0804","article-title":"Dipeptidyl peptidase-4 inhibitors cause bullous pemphigoid in diabetic patients: report of two cases","volume":"34","author":"Pasmatzi","year":"2011","journal-title":"Diabetes Care."},{"key":"B38","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1111\/j.1468-3083.2011.04062.x","article-title":"Drug-induced bullous pemphigoid in diabetes mellitus patients receiving dipeptidyl peptidase-IV inhibitors plus metformin","volume":"26","author":"Skandalis","year":"2012","journal-title":"J Eur Acad Dermatol Venereol."},{"key":"B39","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1001\/jamadermatol.2013.1073","article-title":"A case report of bullous pemphigoid induced by dipeptidyl peptidase-4 inhibitors","volume":"149","author":"Aouidad","year":"2013","journal-title":"JAMA Dermatol."},{"key":"B40","doi-asserted-by":"publisher","first-page":"24","DOI":"10.3315\/jdcr.2014.1166","article-title":"Bullous pemphigoid associated with dipeptidyl peptidase IV inhibitors","volume":"8","author":"Attaway","year":"2014","journal-title":"A case report and review of literature J Dermatol Case Rep."},{"key":"B41","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1111\/fcp.12083","article-title":"Bullous pemphigoid induced by vildagliptin: a report of three cases","volume":"29","author":"Bene","year":"2015","journal-title":"Fundamental Clin Pharmacol."},{"key":"B42","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1159\/000443330","article-title":"Three cases of bullous pemphigoid associated with dipeptidyl peptidase-4 inhibitors-one due to linagliptin","volume":"232","author":"Mendon\u00e7a","year":"2016","journal-title":"Dermatology."},{"key":"B43","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1111\/jcpt.12397","article-title":"Dipeptidyl peptidase-IV inhibitors induced bullous pemphigoid: a case report and analysis of cases reported in the European pharmacovigilance database","volume":"41","author":"Garc\u00eda","year":"2016","journal-title":"J Clin Pharm Therapeut."},{"key":"B44","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1001\/jamadermatol.2015.2939","article-title":"Bullous pemphigoid associated with linagliptin treatment","volume":"152","author":"Haber","year":"2016","journal-title":"JAMA Dermatol."},{"key":"B45","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1111\/bjd.15111","article-title":"Linagliptin-associated bullous pemphigoid that was most likely caused by IgG autoantibodies against the midportion of BP180","volume":"176","author":"Sakai","year":"2017","journal-title":"Br J Dermatol."},{"key":"B46","doi-asserted-by":"publisher","first-page":"1467","DOI":"10.1111\/ijd.13705","article-title":"Linagliptin-induced bullous pemphigoid","volume":"56","author":"Esposito","year":"2017","journal-title":"Int J Dermatol."},{"key":"B47","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1111\/jdi.12695","article-title":"Bullous pemphigoid associated with dipeptidyl peptidase-4 inhibitors: a report of five cases","volume":"9","author":"Yoshiji","year":"2018","journal-title":"J Diabetes Invest."},{"key":"B48","doi-asserted-by":"publisher","first-page":"2471","DOI":"10.2169\/internalmedicine.8703-16","article-title":"Bullous pemphigoid associated with the dipeptidyl peptidase-4 inhibitor sitagliptin in a patient with liver cirrhosis complicated with rapidly progressive hepatocellular carcinoma","volume":"56","author":"Harada","year":"2017","journal-title":"Intern Med."},{"key":"B49","doi-asserted-by":"publisher","first-page":"e238","DOI":"10.1111\/1346-8138","article-title":"Bullous pemphigoid following the replacement of vildagliptin with anagliptin","volume":"44","author":"Oya","year":"2017","journal-title":"J Dermatol."},{"key":"B50","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1159\/000480498","article-title":"Use of dipeptidyl-peptidase IV inhibitors and bullous pemphigoid","volume":"233","author":"Schaffer","year":"2017","journal-title":"Dermatology."},{"key":"B51","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1016\/j.jaad.2017.09.051","article-title":"Detection and characterization of IgG, IgE, and IgA autoantibodies in patients with bullous pemphigoid associated with dipeptidyl peptidase-4 inhibitors","volume":"78","author":"Fania","year":"2018","journal-title":"J Am Acad Dermatol."},{"key":"B52","doi-asserted-by":"publisher","first-page":"602","DOI":"10.2340\/00015555-3166","article-title":"Gliptin-associated bullous pemphigoid and the expression of dipeptidyl peptidase-4\/CD26 in bullous pemphigoid","volume":"99","author":"Lindgren","year":"2019","journal-title":"Acta Dermato-Venereol."},{"key":"B53","doi-asserted-by":"publisher","first-page":"1090","DOI":"10.1016\/j.jaad.2017.12.038","article-title":"Dipeptidyl peptidase-IV inhibitors, a risk factor for bullous pemphigoid","volume":"78","author":"Benzaquen","year":"2018","journal-title":"retrospective multicenter case-control study in France and Switzerland J Am Acad Dermatol."},{"key":"B54","doi-asserted-by":"publisher","first-page":"1659","DOI":"10.1016\/j.jid.2018.01.027","article-title":"Vildagliptin significantly increases the risk of bullous pemphigoid: a Finnish nationwide registry study","volume":"138","author":"Varpuluoma","year":"2018","journal-title":"J Invest Dermatol."},{"key":"B55","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1111\/jdi.12877","article-title":"Dipeptidyl peptidase-4 inhibitors-associated bullous pemphigoid: a retrospective study of 168 pemphigoid and 9,304 diabetes mellitus cases","volume":"10","author":"Kawaguchi","year":"2018","journal-title":"J Diabetes Invest."},{"key":"B56","doi-asserted-by":"publisher","first-page":"1152","DOI":"10.1001\/jamadermatol.2018.2352","article-title":"Association of bullous pemphigoid with dipeptidyl-peptidase 4 inhibitors in patients with diabetes: estimating the risk of the new agents and characterizing the patients","volume":"154","author":"Kridin","year":"2018","journal-title":"JAMA Dermatol."},{"key":"B57","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1016\/j.jid.2018.10.045","article-title":"Higher frequency of dipeptidyl peptidase IV inhibitor intake in bullous pemphigoid patients than in the french general population","volume":"139","author":"Plaquevent","year":"2019","journal-title":"J Invest Dermatol."},{"key":"B58","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1001\/jamadermatol.2018.4556","article-title":"Association of dipeptidyl peptidase 4 inhibitor use with risk of bullous pemphigoid in patients with diabetes","volume":"155","author":"Lee","year":"2019","journal-title":"JAMA Dermatol."},{"key":"B59","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1016\/j.jaad.2018.07.008","article-title":"Bullous disorders associated with anti\u2013PD-1 and anti\u2013PD-L1 therapy: a retrospective analysis evaluating the clinical and histopathologic features, frequency, and impact on cancer therapy","volume":"79","author":"Siegel","year":"2018","journal-title":"J Am Acad Dermatol."},{"key":"B60","doi-asserted-by":"publisher","first-page":"268","DOI":"10.3389\/fmed.2018.00268","article-title":"Mucous membrane pemphigoid, bullous pemphigoid, and anti-programmed death-1\/programmed death-ligand 1: a case report of an elderly woman with mucous membrane pemphigoid developing after pembrolizumab therapy for metastatic melanoma and review of the literature","volume":"5","author":"Zumelzu","year":"2018","journal-title":"Front Med."},{"key":"B61","doi-asserted-by":"publisher","first-page":"387","DOI":"10.3389\/fimmu.2015.00387","article-title":"The dipeptidyl peptidase family, prolyl oligopeptidase, and prolyl carboxypeptidase in the immune system and inflammatory disease, including atherosclerosis","volume":"6","author":"Waumans","year":"2015","journal-title":"Front Immunol."},{"key":"B62","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1016\/j.it.2008.02.010","article-title":"Revisiting an old acquaintance: CD26 and its molecular mechanisms in T cell function","volume":"29","author":"Ohnuma","year":"2008","journal-title":"Trends Immunol."},{"key":"B63","doi-asserted-by":"publisher","first-page":"1264","DOI":"10.1111\/j.1365-2133.2008.08515.x","article-title":"CD26\/dipeptidyl-peptidase IV in psoriatic skin: upregulation and topographical changes","volume":"158","author":"Van Lingen","year":"2008","journal-title":"Br J Dermatol."},{"key":"B64","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1093\/ehjcvp\/pvv044","article-title":"Gliptins and their target dipeptidyl peptidase 4: implications for the treatment of vascular disease","volume":"2","author":"Remm","year":"2015","journal-title":"Eur Heart J Cardiovasc Pharmacother."},{"key":"B65","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1016\/j.tips.2009.08.003","article-title":"Dipeptidyl peptidase inhibitors, an emerging drug class for inflammatory disease?","volume":"30","author":"Yazbeck","year":"2009","journal-title":"Trends Pharmacol Sci."},{"key":"B66","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/j.ijcard.2015.07.044","article-title":"DPP-4 inhibition ameliorates atherosclerosis by priming monocytes into M2 macrophages","volume":"199","author":"Brenner","year":"2015","journal-title":"Int J Cardiol."},{"key":"B67","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1111\/bjd.14601","article-title":"Bullous pemphigoid and dipeptidyl peptidase IV inhibitors: a case-noncase study in the French pharmacovigilance database","volume":"175","author":"Bene","year":"2016","journal-title":"Br J Dermatol."},{"key":"B68","doi-asserted-by":"publisher","first-page":"e132","DOI":"10.2337\/dc18-0210dc18-0210","article-title":"Bullous pemphigoid and dipeptidyl peptidase 4 inhibitors: a disproportionality analysis based on the Japanese adverse drug event report database","volume":"41","author":"Arai","year":"2018","journal-title":"Diabetes Care."},{"key":"B69","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1684\/ejd.2018.3371","article-title":"bullous pemphigoid in patients with DPP-4 inhibitors at the onset of disease: does this differ from common bullous pemphigoid?","volume":"28","author":"Patsatsi","year":"2018","journal-title":"Eur J Dermatol."},{"key":"B70","doi-asserted-by":"publisher","first-page":"2201","DOI":"10.1016\/j.jid.2016.06.622","article-title":"Autoantibody profile differentiates between inflammatory and noninflammatory bullous pemphigoid","volume":"136","author":"Izumi","year":"2016","journal-title":"J Invest Dermatol."},{"key":"B71","doi-asserted-by":"publisher","first-page":"1462","DOI":"10.1111\/bjd.16479","article-title":"Unique clinical and serological features of bullous pemphigoid associated with dipeptidyl peptidase-4 inhibitors","volume":"178","author":"Horikawa","year":"2018","journal-title":"Br J Dermatol."},{"key":"B72","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.1016\/j.jid.2017.11.023","article-title":"HLA-DQB1* 03: 01 as a biomarker for genetic susceptibility to bullous pemphigoid induced by DPP-4 inhibitors","volume":"138","author":"Ujiie","year":"2018","journal-title":"J Invest Dermatol."},{"key":"B73","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1016\/S0923-1811(02)00109-3","article-title":"BP180 ELISA using bacterial recombinant NC16a protein as a diagnostic and monitoring tool for bullous pemphigoid","volume":"30","author":"Kobayashi","year":"2002","journal-title":"J Dermatol Sci."},{"key":"B74","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1001\/jamadermatol.2017.5465","article-title":"Clinical and immunological profiles of 14 patients with bullous pemphigoid without IgG autoantibodies to the BP180 NC16A domain","volume":"154","author":"Nakama","year":"2018","journal-title":"JAMA Dermatol."},{"key":"B75","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1016\/j.jaad.2011.06.032","article-title":"Definitions and outcome measures for bullous pemphigoid: recommendations by an international panel of experts","volume":"66","author":"Murrell","year":"2012","journal-title":"J Am Acad Dermatol."},{"key":"B76","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1111\/j.1365-2133.2005.06998.x","article-title":"Bullous pemphigoid antigen II (BP180) and its soluble extracellular domains are major autoantigens in mucous membrane pemphigoid: the pathogenic relevance to HLA class II alleles and disease severity","volume":"154","author":"Oyama","year":"2006","journal-title":"Br J Dermatol."},{"key":"B77","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/s0923-1811(03)00035-5","article-title":"Cicatricial pemphigoid sera specifically react with the most C-terminal portion of BP180","volume":"32","author":"Lee","year":"2003","journal-title":"J Dermatol Sci."},{"key":"B78","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.1111\/bjd.17690","article-title":"Epitope-spreading phenomena in dipeptidyl peptidase-4 inhibitor-associated bullous pemphigoid","volume":"180","author":"Garc\u00eda-D\u00edez","year":"2019","journal-title":"Br J Dermatol."},{"key":"B79","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1111\/bjd.16656","article-title":"Detection of anti-BP 180 NC 16A autoantibodies after the onset of dipeptidyl peptidase-IV inhibitor-associated bullous pemphigoid: a report of three cases","volume":"179","author":"Mai","year":"","journal-title":"Br J Dermatol."},{"key":"B80","doi-asserted-by":"publisher","first-page":"983","DOI":"10.2340\/00015555-3010","article-title":"Dipeptidyl peptidase-4 inhibitor-associated bullous pemphigoid: recurrence with epitope spreading","volume":"98","author":"Takama","year":"2018","journal-title":"Acta Dermato-Venereol."},{"key":"B81","doi-asserted-by":"publisher","first-page":"1120","DOI":"10.4049\/jimmunol.181.2.1120","article-title":"Inhibition of CD26\/dipeptidyl peptidase IV enhances CCL11\/eotaxin-mediated recruitment of eosinophils in vivo","volume":"181","author":"Forssmann","year":"2008","journal-title":"J Immunol."},{"key":"B82","doi-asserted-by":"publisher","first-page":"1610","DOI":"10.2741\/2785","article-title":"Dipeptidyl peptidase IV (DPP IV\/CD26) is a cell-surface plasminogen receptor","volume":"13","author":"Gonzalez-Gronow","year":"2008","journal-title":"Front Biosci."},{"key":"B83","doi-asserted-by":"publisher","first-page":"1730","DOI":"10.1038\/jid.2008.424","article-title":"Plasmin plays a role in the in vitro generation of the linear IgA dermatosis antigen LADB97","volume":"129","author":"Hofmann","year":"2009","journal-title":"J Invest Dermatol."},{"key":"B84","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1093\/hmg\/ddv478","article-title":"Extracellular cleavage of collagen XVII is essential for correct cutaneous basement membrane formation","volume":"25","author":"Nishimura","year":"2015","journal-title":"Hum Mol Genet."},{"key":"B85","doi-asserted-by":"publisher","first-page":"e40","DOI":"10.1111\/1346-8138.14076","article-title":"Pemphigus vulgaris developing after 6-month treatment with a dipeptidyl peptidase-4 inhibitor: a case report","volume":"45","author":"Okauchi","year":"2018","journal-title":"J Dermatol."},{"key":"B86","doi-asserted-by":"publisher","first-page":"518","DOI":"10.2337\/db17-0934","article-title":"DPP-4 inhibitors improve diabetic wound healing via direct and indirect promotion of epithelial-mesenchymal transition and reduction of scarring","volume":"67","author":"Long","year":"2018","journal-title":"Diabetes."},{"key":"B87","doi-asserted-by":"publisher","first-page":"4938","DOI":"10.4049\/jimmunol.1001524","article-title":"Ectodomain shedding generates neoepitopes on collagen XVII, the major autoantigen for bullous pemphigoid","volume":"185","author":"Nishie","year":"2010","journal-title":"J Immunol."},{"key":"B88","doi-asserted-by":"publisher","first-page":"2027","DOI":"10.1016\/S0002-9440(10)63762-5","article-title":"Keratinocytes from patients lacking collagen XVII display a migratory phenotype","volume":"164","author":"Tasanen","year":"2004","journal-title":"Am J Pathol."},{"key":"B89","doi-asserted-by":"publisher","first-page":"2827","DOI":"10.1021\/pr8010974","article-title":"Secretome-based proteomic profiling of ras-transformed MDCK cells reveals extracellular modulators of epithelial-mesenchymal transition","volume":"8","author":"Mathias","year":"2009","journal-title":"J Proteome Res."},{"key":"B90","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1038\/sj.jid.5701104","article-title":"Inhibitors of dipeptidyl peptidase IV-like activity mediate antifibrotic effects in normal and keloid-derived skin fibroblasts","volume":"128","author":"Thielitz","year":"2008","journal-title":"J Invest Dermatol."},{"key":"B91","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1016\/j.clindermatol.2013.01.006","article-title":"Bullous pemphigoid: etiology, pathogenesis, and inducing factors: facts and controversies","volume":"31","author":"Lo Schiavo","year":"2013","journal-title":"Clin Dermatol."},{"key":"B92","doi-asserted-by":"publisher","first-page":"542","DOI":"10.3389\/fimmu.2018.00542","article-title":"Bullous pemphigoid triggered by thermal burn under medication with a dipeptidyl peptidase-IV inhibitor: a case report and review of the literature","volume":"9","author":"Mai","year":"","journal-title":"Front Immunol."},{"key":"B93","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1016\/j.jid.2018.11.025","article-title":"Gliptin-associated bullous pemphigoid: a valuable model of the mechanism of breakdown of immune tolerance against BP180","volume":"139","author":"Nishie","year":"2019","journal-title":"The Journal of Investigative Dermatology."}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fimmu.2019.01238\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,4]],"date-time":"2019-06-04T04:45:07Z","timestamp":1559623507000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fimmu.2019.01238\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6,4]]},"references-count":93,"alternative-id":["10.3389\/fimmu.2019.01238"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2019.01238","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,6,4]]},"article-number":"1238"}}